Most analysts are positive on the company’s future prospects and suggest subscribing to the issue. They believe the company, which is a spin off of Glenmark Pharma, is well placed in the Active Pharmaceutical Ingredient (API) business.
Glenmark Life Sciences IPO sails through within 90 minutes
More from Industry NewsMore posts in Industry News »
- Frontline, medical workers need to take booster shots, say experts
- India tells Quad will allow export of 8 mln Indo-Pacific vaccine doses
- We need to be vigilant towards counterfeit products: Nakul Pasricha,President, ASPA
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference